Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab Deruxtecan in Brain Metastases
NCT05620914Phase 2Withdrawn
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in brain metastases. Primary endpoint: Concentration of DXd in brain metastasis tumor tissue at 3 days. Planned start Jul 2025; status: withdrawn.
02
Drugs
patritumab deruxtecan
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT05620914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620914.